Streetbeat News

Revenues

TVGN

Tevogen Bio shares increased following the company's revenue projections for its SARS-CoV-2 treatment in cancer patients and its focus on additional therapeutic areas and long-term innovation goals.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 2:04 pm

LULU

Lululemon Athletica (NASDAQ:LULU) has significantly outperformed the market over the past 15 years, with an annualized return of 23.33%. A $1000 investment in LULU 15 years ago would be worth $22,882.57 today, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 2:01 pm

STRL

Sterling Infrastructure (NASDAQ:STRL) has significantly outperformed the market over the past 5 years, with an average annual return of 58.82%. A $100 investment in STRL 5 years ago would now be worth $1,013.70. The article highlights the impact of compounded returns on investment growth.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 2:01 pm

SGD

Safe and Green Development shares rose following a shareholder letter detailing strategic growth plans and expected revenue from South Texas in 2025.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 2:00 pm

SR

Analysts have mixed ratings for Spire (NYSE:SR), with recent evaluations showing a shift towards bearish sentiment. The average 12-month price target has increased slightly to $69.88. Spire faces financial challenges, including a decline in revenue and below-average profitability metrics.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 2:00 pm

JKHY

Jack Henry & Associates (NASDAQ:JKHY) has been analyzed by five analysts, showing a range of sentiments from somewhat bullish to indifferent. The average 12-month price target is $189.6, up 4.46% from the previous target. Analysts have adjusted their ratings and price targets, reflecting their views on the company's market position. Jack Henry is a leading provider of core processing services for banks and credit unions, with strong net margins and efficient asset use, but faces challenges in revenue growth and return on equity.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 2:00 pm

CCI

Crown Castle (NYSE:CCI) has been analyzed by 8 analysts, showing a range of ratings from bullish to indifferent. Recent analyst actions include both raised and lowered price targets, with an average 12-month target of $116.75, up 4.35% from the previous average. Despite positive analyst sentiment, Crown Castle faces financial challenges, including a -12.91% revenue decline, low net margin, and high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 2:00 pm

SPY

Retail inventories in the USA, excluding autos, increased by 0.5% in August, surpassing the estimated 0.4% and matching the prior month's growth.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 2:00 pm

SPY

The NAHB Housing Market Index for October remained steady at 43, matching expectations and showing no change from the previous month. This indicates a stable sentiment in the housing market.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 2:00 pm

LXRX

Lexicon Pharmaceuticals (NASDAQ:LXRX) has been evaluated by 8 analysts over the past three months, with all ratings being bullish. The average 12-month price target remains at $10.00. Despite strong revenue growth, the company faces challenges with profitability and returns on equity and assets.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 2:00 pm